Namodenoson Shows Promise in Treating Decompensated Liver Cirrhosis: Patient's Remarkable Recovery in Compassionate Use Program
Key Insights
A patient with decompensated liver cirrhosis (search) demonstrated significant clinical improvement after 20 months of Namodenoson treatment, including resolution of moderate ascites and no further variceal bleeding episodes.
Can-Fite BioPharma's Namodenoson emerges as a potential breakthrough for decompensated cirrhosis patients, addressing a critical gap in treatment options beyond liver transplantation.
The development holds significant promise for the estimated 10.6 million people globally affected by decompensated cirrhosis, targeting a U.S. market projected to reach $15 billion by 2030.
In a significant breakthrough for liver disease treatment, Can-Fite BioPharma has reported remarkable clinical improvements in a patient with decompensated liver cirrhosis (search) treated with Namodenoson under a compassionate use program. The development offers new hope for patients facing limited treatment options beyond liver transplantation.
Clinical Response and Symptom Improvements
After 20 months of treatment, the patient experienced substantial improvements across multiple disease markers. Notable developments include:
- Complete resolution of moderate ascites, eliminating the need for diuretics for over a year
- No recurrence of esophageal variceal bleeding episodes
- Significant reduction in fatigue and edema
- Measurable decrease in liver stiffness compared to pre-treatment levels
- Declining globulin levels, indicating improvement in liver function
Expert Perspective on Treatment Impact
Dr. Ohad Etzion, Chief of Gastrointestinal and Liver Diseases at Soroka Medical Center (search) in Israel, emphasized the significance of these results: "The patient's positive response to Namodenoson is extremely encouraging. We currently have very limited options for treating patients with decompensated liver disease beyond liver transplantation. Unfortunately, due to a shortage of donor organs, many patients die while waiting for a transplant."
Disease Burden and Market Need
The development addresses a critical medical need in liver disease treatment:
- Global impact: An estimated 10.6 million people affected by decompensated cirrhosis as of 2017
- Limited options: Current treatment landscape restricted primarily to liver transplantation
- Organ shortage: Extended waiting periods for transplants, often exceeding five years
- Market potential: U.S. liver cirrhosis treatment market projected to reach $15 billion by 2030
About Namodenoson
Namodenoson is an orally administered small molecule drug that specifically targets the A3 adenosine receptor (search) (A3AR). The drug's development program includes:
- Ongoing pivotal Phase III trial for advanced liver cancer
- Phase IIb trial for Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Phase IIa study in pancreatic cancer
The drug's selective binding to A3AR, which is highly expressed in diseased cells but minimal in normal cells, contributes to its favorable safety profile. This characteristic makes it particularly promising for long-term treatment of chronic liver conditions.